Compare DexCom, Inc. (DXCM) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Microchip Technology Inc. — how do they compare? DexCom, Inc. trades at $77.82 (market cap $28.06B), while Microchip Technology Inc. trades at $82.97 (market cap $46.84B). The key difference: Microchip Technology Inc. is the larger of the two by market cap, and Microchip Technology Inc. pays a 2.11% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MCHP | |
|---|---|---|
Market Cap | $28.06B | $46.84B |
Sector | Health | Technology |
52-Week High | $89.53 | $102.97 |
52-Week Low | $54.84 | $49.02 |
Enterprise Value | $27.03B | $52.13B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MCHP trades at $87.11, up 3.42% today, with a neutral technical signal and bullish moving averages. The stock has beaten EPS estimates for three consecutive quarters, though 2025 saw a net loss. Analyst consensus is strongly bullish with a $113.33 price target, supported by positive news on AI, industrial IoT, and aerospace demand.
The outlook is positive given strong analyst support and exposure to growth markets, but high valuation ratios and recent profitability pressures pose risks. Upside depends on continued earnings beats and sector recovery, while debt levels and margin volatility require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
